Retatrutide, developed by Soma Corp., is gaining considerable attention as a innovative method for obesity management . This dual-action compound merges the mechanism of a GLP-1 receptor activator and a GIP receptor activator , aiming to not only promote reduced body fat but also target underlying metabolic issues . Early patient trials have shown